Business, energy, technology, markets and global industry news from Business News Today

CU Anschutz Cancer Center

PharmaDeviceNews CU Anschutz Cancer Center
Next-generation CAR T cell therapy research advances as the US Food and Drug Administration clears a University of Colorado Anschutz Medical Campus clinical trial evaluating B7-H3 CAR T cells engineered to follow IL-8 signals into colorectal cancer and pediatric solid tumors. Representative image.
Pharma & Biotech

FDA clears University of Colorado Anschutz CAR T trial for colorectal and pediatric solid tumors

FDA clears a CU Anschutz trial of B7-H3 CAR T cells engineered to follow IL-8 signals into colorectal and pediatric solid tumors.

Read More